Search Results

You are looking at 91 - 100 of 496 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver

UMCCC experienced more rapid transition from biopsy to surgery or neoadjuvant chemotherapy, and surgery to adjuvant chemotherapy than those who received a portion of their care outside the center. This finding is not surprising, because EHR and internal

Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman

1984 ; 2 : 1281 – 1288 . 4. Link BK Budd GT Scott S . Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care . Cancer 2001 ; 92 : 1354 – 1367 . 5. Lyman GH Dale DC Crawford J

Full access

Craig A. Bunnell, Katya Losk, Sarah Kadish, Nancy Lin, Judith Hirshfield-Bartek, Linda Cutone, Kristen Camuso, Mehra Golshan, and Saul Weingart

groups were created to improve the coordination of care transitions. For example, to expedite the timing of adjuvant chemotherapy, a team of front-line administrative staff from medical and surgical oncology departments was formed to develop new workflows

Full access

Katherine Van Loon and Alan P. Venook

-risk stage II colon cancer. A Review of the Literature The existing literature on the role for adjuvant chemotherapy in stage II colon cancer is summarized in Table 1 . The QUASAR trial randomized 2291 patients with completely resected stage II colon

Full access

Zhong Ye, Chun Wang, Limin Guo, Juan P. Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A. Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, and Hushan Yang

Colorectal cancer (CRC) is highly treatable by surgical removal if diagnosed at an early stage, and the 5-year survival rate for localized CRC is estimated to be 90%. 1 Adjuvant chemotherapy has been clinically proven to reduce CRC recurrence

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass

that some patients with disease at lower risk of local recurrence (eg, proximal rectal cancer staged as T3,N0,M0, characterized by clear margins and favorable prognostic features) may be adequately treated with surgery and adjuvant chemotherapy. 108

Full access

Margaret A. Tempero, Mokenge P. Malafa, E. Gabriela Chiorean, Brian Czito, Courtney Scaife, Amol K. Narang, Christos Fountzilas, Brian M. Wolpin, Mahmoud Al-Hawary, Horacio Asbun, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, Vincent Chung, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, George Fisher, Jeffrey Hardacre, William G. Hawkins, Andrew H. Ko, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O’Reilly, Jorge Obando, Sushanth Reddy, Sarah Thayer, Robert A. Wolff, Jennifer L. Burns, and Griselda Zuccarino-Catania

did not (21% vs 8%, respectively; P =.009). These results did not eliminate 5-FU–based CRT as an acceptable choice in the adjuvant setting, but did provide evidence to support adjuvant chemotherapy alone. A more contemporary study compared different

Full access

Robert B. Hines, Alina Barrett, Philip Twumasi-Ankrah, Dominique Broccoli, Kimberly K. Engelman, Joaquina Baranda, Elizabeth A. Ablah, Lisette Jacobson, Michelle Redmond, Wei Tu, and Tracie C. Collins

events 46 and also derive a benefit from receiving neoadjuvant/adjuvant chemotherapy/radiation. 21 In the stratified analysis across levels of comorbidity, patients who received nonadherent treatment at all levels of comorbidity had increased risks of

Full access

Sujana Movva, Margaret von Mehren, Eric A. Ross, and Elizabeth Handorf

a meta-analysis of 14 randomized trials of doxorubicin-based adjuvant chemotherapy for STS from a variety of primary sites. There was a benefit for local and distant recurrence-free intervals and overall recurrence-free survival favoring the

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

. 22 Furthermore, single-institution retrospective trials magnify the risk of selection bias, making these results difficult for clinicians to apply to a given elderly patient. Role of Adjuvant Chemotherapy Adjuvant chemotherapy after resection